INN monograph
Ilaprazole
Proton pump inhibitor (PPI) · POM
Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; Professional class pharmacology (Proton pump inhibitor (PPI))
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- Hypersensitivity to PPIs.
- Caution with rilpivirine and some antivirals (gastric pH).
Precautions
- Use lowest effective dose/shortest duration.
- Long-term: hypomagnesaemia, B12 deficiency, increased GI infection risk, fracture signal, fundic polyps.
- Masking of malignancy — investigate alarm features.
Point of care
Dosing
Adult
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Renal
Rare AIN; otherwise minimal renal dosing issues.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
Severe hepatic impairment: dose reduction for some agents.
Safety
Drug interactions
- Step-down after healing peptic disease.
- Test-and-treat or empiric strategies per local dyspepsia pathways.
- Review chronic PPI prescriptions for deprescribing eligibility.
Safety
Adverse effects
- Candidiasis, GI disturbances, skin rashes, photosensitivity, stomatitis blood dyscrasia, hypersensitivity, CNS effects, paraesthesia, malaise, alopecia, muscle weakness, myalgia, peripheral edema, gynecomastia, hepatitis.
Use
Indications
- Duodenal ulcers, benign gastric ulcers, and prevention of peptic ulcers associated with NSAIDs, reflux oesophagitis, Zollinger-Ellison syndrome Clinical selection for Ilaprazole should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Proton pump inhibitor (PPI).
- Confirm site-specific dose, duration and monitoring before prescribing.
Pharmacology
Mode of action
PPIs irreversibly inhibit the gastric H+/K+-ATPase (proton pump) in parietal cells, suppressing basal and stimulated acid secretion — the most potent pharmacological acid suppression.
Full mechanism text
PPIs irreversibly inhibit the gastric H+/K+-ATPase (proton pump) in parietal cells, suppressing basal and stimulated acid secretion — the most potent pharmacological acid suppression.
ADME
Pharmacokinetics & PD
| Onset | 1–2 hours; full acid suppression days |
|---|---|
| Duration | 24 hours+ (irreversible pump inhibition) |
| Route | ORAL / IV |
| Metabolism | (polymorphisms affect levels). Short plasma |
| Half-life | but prolonged pharmacodynamic effect. |
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| Ilapraz | Prism Life Sciences | Standard Commercial Pack | 598.09 |
Special populations
Pregnancy & lactation
Pregnancy
Often used when indicated; omeprazole has substantial human data — still risk–benefit.
Lactation
Generally considered acceptable; infant exposure low.
Diet
Food & alcohol
- Food
- Food
Trust
Sources & disclaimer
Source: Local active-ingredient clinical extract; Professional class pharmacology (Proton pump inhibitor (PPI))
Last reviewed: 01 Aug 2026
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.